Innovative Immunotherapy Shows Promise Across Multiple Cancer Types

Researchers at MIT and Stanford have developed a new immunotherapy approach using multifunctional molecules called AbLecs that block glycans on cancer cells, potentially making cancer immunotherapy effective for more patients by reversing immune suppression mechanisms.